Konjac Glucomannan Biscuits Significantly Improve Fasting Glucose Control and Weight Loss in Obese Prediabetics
Background
Prediabetes is a critical, reversible condition characterized by elevated blood glucose levels that, if unmanaged, often progresses to type 2 diabetes mellitus (T2DM). Lifestyle interventions, including diet and exercise, are the cornerstone of prevention, yet adherence and efficacy can vary. Dietary fibers like Konjac Glucomannan (KGM), derived from the konjac plant, are recognized for their potential to modulate glucose metabolism, enhance satiety, and support weight management. This study addresses the need for accessible, effective adjunctive strategies to improve glycemic control and reduce obesity-related parameters in individuals at high risk for T2DM.
Study Design
Researchers conducted a three-month randomized controlled trial involving 102 obese individuals diagnosed with prediabetes. Participants were assigned to either a Konjac Glucomannan (KGM) group or a control group. Both groups followed personalized dietary and exercise regimens. The KGM group additionally consumed 60 g of konjac-based dietary fiber biscuits daily, partially replacing carbohydrates. The primary endpoint was the effective rate of fasting blood glucose control, while secondary endpoints included changes in 2-hour postprandial glucose, insulin-related indicators (e.g., fasting insulin, HOMA-IR, HOMA-β), and obesity-related parameters like body mass and waist circumference.
Results
Of the 102 participants, 41 in the KGM group and 38 in the control group completed the trial, with compliance rates of 77.36% and 77.55%, respectively. After three months, the KGM group demonstrated superior glycemic control and metabolic improvements. The effective rate of fasting blood glucose control was 100% in the KGM group, significantly higher than the 82% observed in the control group. The KGM group also showed significantly higher effective rates in reducing fasting insulin, insulin resistance (as measured by HOMA-IR), body mass, and waist circumference compared to the control group (P < 0.05 for all). However, no statistically significant differences were found between groups for body mass index (BMI), 2-hour postprandial blood glucose, 2-hour postprandial insulin, or effective control of pancreatic β-cell activity (P > 0.05).
Key Findings
- KGM group achieved 100% effective rate in fasting blood glucose control, significantly higher than 82% in controls.
- KGM significantly reduced
fasting insulin,insulin resistance,body mass, andwaist circumference(P < 0.05). - No significant differences in
BMI,2-hour postprandial glucose, orpancreatic β-cell activitybetween groups (P > 0.05). - Two participants experienced severe abdominal discomfort, and others reported transient diarrhea or increased flatulence.
Why It Matters
Incorporating Konjac Glucomannan into the daily diet offers a practical and accessible adjunctive strategy for managing prediabetes and obesity. This study suggests that KGM can significantly enhance the efficacy of standard lifestyle interventions in controlling fasting blood glucose and promoting weight loss. For individuals struggling with prediabetes, adding KGM-based dietary fiber could be a valuable tool to improve metabolic health and potentially prevent progression to T2DM. While it didn't impact postprandial glucose as strongly, its effects on fasting glucose, insulin sensitivity, and body composition are clinically meaningful. This provides a simple, food-based protocol addition for those seeking to optimize their metabolic health stack.
konjac glucomannan
prediabetes
obesity
glycemic control
weight loss
dietary fiber